UK markets closed
NIKKEI 225
39,631.06 +47.98 (+0.12%) HANG SENG
17,718.61 +2.11 (+0.01%) CRUDE OIL
83.42 +1.88 (+2.31%) GOLD FUTURES
2,341.10 +1.50 (+0.06%) DOW
39,137.33 +18.47 (+0.05%) Bitcoin GBP
50,194.55 +1,296.67 (+2.65%)
ITCI Nov 2024 65.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 09:30AM EDT. Market open.
| Previous close | 3.0500 |
| Open | 3.0500 |
| Bid | 4.1000 |
| Ask | 5.7000 |
| Strike | 65.00 |
| Expiry date | 2024-11-15 |
| Day's range | 3.0500 - 3.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | 18 |
ZacksIntra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
Investor's Business DailyIntra-Cellular Therapies Stock Scores RS Rating Upgrade To 87
The Relative Strength (RS) Rating for Intra-Cellular Therapies stock entered a new percentile Thursday, with a rise from 75 to 87. This unique rating tracks technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the last 52 weeks matches up against the rest of the market.
ZacksBiotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
© 2024 Yahoo. All rights reserved.